Erlotinib (DrugBank: Erlotinib)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00955149 (ClinicalTrials.gov) | August 2009 | 5/8/2009 | Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7 | Primary Sclerosing Cholangitis;Trisomy 7;Cholangiocarcinoma;Chemoprevention | Drug: Erlotinib (Tarceva) | Mayo Clinic | Genentech, Inc. | Completed | 18 Years | N/A | Both | 6 | Phase 1 | United States |